upbeat comments lilly president dr john lechleiter zyprexa cymbalta regarding zyprexa lechleiter stated marked turning point zyprexa measured four week moving average total prescription share retail volume hospital share zyprexa sales stabilized outside positive findings catie soho studies impact wellness programs managing side effects leading share voice among psychiatrists allowed zyprexa either grow hold major markets lechleiter also comments cymbalta paraphrased cymbalta expected key driver growth lilly cymbalta outperformed branded antidepressants terms share market growth measured new prescriptions total prescriptions globally cymbalta launch one successful lilly history entire antidepressant market worldwide sales grew percent third quarter compared period last year cymbalta track generate billion annual sales second full year market view well nice cymbalta prescriptions running wild even absence consistent data actually reduces pain depressed patients unique marketing angle zyprexa sales well irony department byetta lilly diabetes drug also well era atypical antipsychotics course would expect drugs like byetta really shine soho study hip name drug study fresh i yet read discuss catie results positive zyprexa misleading best